|
IL316479A
(en)
|
2014-06-25 |
2024-12-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
|
|
RS63030B1
(sr)
|
2015-09-17 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
|
|
RS63986B1
(sr)
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
JP7114465B2
(ja)
|
2015-12-22 |
2022-08-08 |
モデルナティエックス インコーポレイテッド |
薬剤の細胞内送達のための化合物および組成物
|
|
EP3397613A1
(en)
*
|
2015-12-30 |
2018-11-07 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
ES3020935T3
(en)
|
2017-03-15 |
2025-05-23 |
Modernatx Inc |
Lipid nanoparticle formulation
|
|
KR20190132405A
(ko)
|
2017-03-15 |
2019-11-27 |
모더나티엑스, 인크. |
치료제의 세포내 전달을 위한 화합물 및 조성물
|
|
CA3056133A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
US12077501B2
(en)
|
2017-06-14 |
2024-09-03 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
JP7550648B2
(ja)
|
2018-03-19 |
2024-09-13 |
クリスパー セラピューティクス アーゲー |
新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用
|
|
WO2020061367A1
(en)
*
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2020061457A1
(en)
*
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
US12583816B2
(en)
|
2018-10-18 |
2026-03-24 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
CA3121191A1
(en)
|
2018-11-28 |
2020-06-04 |
Crispr Therapeutics Ag |
Optimized mrna encoding cas9 for use in lnps
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
MX2021009245A
(es)
*
|
2019-01-31 |
2021-11-12 |
Modernatx Inc |
Metodos de preparacion de nanoparticulas lipidicas.
|
|
US20220145274A1
(en)
|
2019-03-12 |
2022-05-12 |
Crispr Therapeutics Ag |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
|
ES2918001B2
(es)
*
|
2019-08-14 |
2026-05-13 |
Acuitas Therapeutics Inc |
Nanoparticulas lipidicas mejoradas para el suministro de acidos nucleicos
|
|
MX2022003269A
(es)
|
2019-09-19 |
2022-07-04 |
Modernatx Inc |
Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos.
|
|
CA3155015A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2020352552A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
|
|
CN114391040A
(zh)
|
2019-09-23 |
2022-04-22 |
欧米茄治疗公司 |
用于调节载脂蛋白b(apob)基因表达的组合物和方法
|
|
CN114980920A
(zh)
|
2019-11-18 |
2022-08-30 |
詹森生物科技公司 |
基于突变体calr和jak2的疫苗及其用途
|
|
CN114901360A
(zh)
|
2019-12-20 |
2022-08-12 |
库瑞瓦格股份公司 |
用于递送核酸的新型脂质纳米颗粒
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
CA3170142A1
(en)
*
|
2020-02-19 |
2021-08-26 |
Nammi Therapeutics, Inc. |
Formulated and/or co-formulated liposome compositions containing tfgb antagonist prodrugs useful in the treatment of cancer and methods thereof
|
|
WO2021183720A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
IL296781A
(en)
|
2020-03-30 |
2022-11-01 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
CN113521269A
(zh)
|
2020-04-22 |
2021-10-22 |
生物技术Rna制药有限公司 |
冠状病毒疫苗
|
|
TW202206097A
(zh)
|
2020-05-20 |
2022-02-16 |
美商旗艦先鋒創新有限責任公司 |
冠狀病毒抗原組成物及其用途
|
|
EP4153223A1
(en)
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
IL298539A
(en)
|
2020-05-29 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Trem compositions and methods relating thereto
|
|
CA3182026A1
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
CA3185041A1
(en)
|
2020-07-13 |
2022-01-20 |
Edward Asirvatham |
Branched amino acid surfactants for use in healthcare products
|
|
EP4208196A1
(en)
|
2020-09-03 |
2023-07-12 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
CZ310613B6
(cs)
|
2020-09-23 |
2026-01-28 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
KR20230118715A
(ko)
|
2020-10-14 |
2023-08-11 |
조지 메이슨 리서치 파운데이션 인코포레이티드 |
이온화 가능 지질 및 이의 제조 및 사용 방법
|
|
US11771652B2
(en)
|
2020-11-06 |
2023-10-03 |
Sanofi |
Lipid nanoparticles for delivering mRNA vaccines
|
|
US11058751B1
(en)
|
2020-11-20 |
2021-07-13 |
Think Therapeutics, Inc. |
Compositions for optimized RAS peptide vaccines
|
|
CN116710115A
(zh)
|
2020-11-20 |
2023-09-05 |
思维疗法股份有限公司 |
用于优化的肽疫苗的组合物和方法
|
|
US11421015B2
(en)
|
2020-12-07 |
2022-08-23 |
Think Therapeutics, Inc. |
Method of compact peptide vaccines using residue optimization
|
|
CA3200234A1
(en)
|
2020-11-25 |
2022-06-02 |
Daryl C. Drummond |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
|
BR112023012377A2
(pt)
|
2020-12-23 |
2023-10-24 |
Flagship Pioneering Innovations Vi Llc |
Composições de trems modificadas e usos das mesmas
|
|
US20240226025A1
(en)
*
|
2021-03-24 |
2024-07-11 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
|
AU2022245247A1
(en)
*
|
2021-03-24 |
2023-10-05 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
US20220325287A1
(en)
|
2021-03-31 |
2022-10-13 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
WO2022215036A1
(en)
|
2021-04-08 |
2022-10-13 |
Vaxthera Sas |
Coronavirus vaccine comprising a mosaic protein
|
|
EP4321503A4
(en)
*
|
2021-04-08 |
2024-10-09 |
Xiamen Sinopeg Biotech Co., Ltd. |
PEGYLATED LIPID, LIPOSOME THUS MODIFIED, PHARMACEUTICAL COMPOSITION CONTAINING A LIPOSOME, ASSOCIATED PREPARATION AND USE
|
|
AU2022256732A1
(en)
|
2021-04-12 |
2023-10-19 |
Biontech Delivery Technologies Gmbh |
Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
|
|
US11464842B1
(en)
|
2021-04-28 |
2022-10-11 |
Think Therapeutics, Inc. |
Compositions and method for optimized peptide vaccines using residue optimization
|
|
US20240321387A1
(en)
|
2021-05-04 |
2024-09-26 |
BioNTech SE |
Immunogen selection
|
|
WO2022247801A1
(zh)
*
|
2021-05-28 |
2022-12-01 |
北京启辰生生物科技有限公司 |
脂质化合物及其在核酸递送中的应用
|
|
EP4101928A1
(en)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Type v rna programmable endonuclease systems
|
|
IL308896A
(en)
|
2021-06-11 |
2024-01-01 |
Bayer Ag |
Type v rna programmable endonuclease systems
|
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
JP2024525795A
(ja)
|
2021-07-15 |
2024-07-12 |
バイオエヌテック エスエー |
Ｃｌｄｎ６陽性癌を治療するための、ｃｌｄｎ６およびｃｄ３結合要素をコードする薬剤
|
|
CZ310443B6
(cs)
|
2021-07-19 |
2025-06-25 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
WO2023001286A1
(zh)
*
|
2021-07-23 |
2023-01-26 |
天津键凯科技有限公司 |
一种多元甘醇修饰的脂质化合物及其制备方法和应用
|
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
|
WO2023006920A1
(en)
|
2021-07-29 |
2023-02-02 |
BioNTech SE |
Compositions and methods for treatment of melanoma
|
|
CN115703714B
(zh)
*
|
2021-08-13 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115710191B
(zh)
*
|
2021-08-23 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115710193B
(zh)
*
|
2021-08-23 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
EP4141013A1
(en)
*
|
2021-08-31 |
2023-03-01 |
Studiengesellschaft Kohle mbH |
Stereochemically pure lipids for nucleic acid delivery
|
|
WO2023030635A1
(en)
|
2021-09-02 |
2023-03-09 |
BioNTech SE |
Potency assay for therapeutic potential of coding nucleic acid
|
|
IL309505A
(en)
|
2021-09-03 |
2024-02-01 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
CA3229889A1
(en)
|
2021-09-03 |
2023-03-09 |
Glaxosmithkline Biologicals Sa |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
|
EP4144841A1
(en)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
|
|
EP4402121A1
(en)
|
2021-09-14 |
2024-07-24 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
DK4271818T3
(da)
|
2021-09-17 |
2024-11-04 |
Flagship Pioneering Innovations Vi Llc |
Sammensætninger og fremgangsmåder til fremstilling af cirkulære polyribonukleotider
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
AR127312A1
(es)
*
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
KR20230053998A
(ko)
|
2021-10-15 |
2023-04-24 |
(주)지노믹트리 |
mRNA 발현을 위한 유전자 구조체
|
|
US20240417714A1
(en)
|
2021-10-18 |
2024-12-19 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
WO2023067193A2
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Compositions for administration of different doses of rna
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
WO2023083434A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
|
|
KR102772764B1
(ko)
|
2021-11-10 |
2025-02-27 |
주식회사 에스엠엘바이오팜 |
트레할로즈 유도체 및 신규 구조 유지 화합물을 포함하는 핵산 의약품 전달용 지질나노입자의 약학 조성물
|
|
CA3238370A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Varicella-zoster virus immunogen compositions and their uses
|
|
IL312965A
(en)
|
2021-11-24 |
2024-07-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and their uses
|
|
CN118900845A
(zh)
|
2021-11-24 |
2024-11-05 |
旗舰创业创新六公司 |
冠状病毒免疫原组合物及其用途
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
MX2024007307A
(es)
|
2021-12-17 |
2024-08-06 |
Flagship Pioneering Innovations Vi Llc |
Métodos de enriquecimiento de arn circular en condiciones desnaturalizantes.
|
|
AU2022417517A1
(en)
|
2021-12-22 |
2024-06-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
CA3243301A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
NEW SMALL PROGRAMMABLE TYPE V RNA ENDONUCLEASE SYSTEMS
|
|
US20230201817A1
(en)
|
2021-12-23 |
2023-06-29 |
Biontech Delivery Technologies Gmbh |
Modular drug production system
|
|
MX2024007870A
(es)
|
2021-12-23 |
2024-08-15 |
Flagship Pioneering Innovations Vi Llc |
Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
|
|
WO2023126053A1
(en)
|
2021-12-28 |
2023-07-06 |
BioNTech SE |
Lipid-based formulations for administration of rna
|
|
CN114044741B
(zh)
*
|
2022-01-13 |
2022-04-15 |
北京悦康科创医药科技股份有限公司 |
一种阳离子脂质化合物、包含其的组合物及用途
|
|
EP4469063A1
(en)
|
2022-01-27 |
2024-12-04 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
AU2023216437A1
(en)
|
2022-02-02 |
2024-08-15 |
BioNTech SE |
Agents and methods for targeted delivery of nucleic acids to cells
|
|
WO2023148276A1
(en)
|
2022-02-02 |
2023-08-10 |
BioNTech SE |
Agents and methods for targeted delivery to cells
|
|
WO2023156487A1
(en)
|
2022-02-15 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating tear film composition to treat corneal defects
|
|
AU2023238872A1
(en)
*
|
2022-03-22 |
2024-11-07 |
Arnold S. Lippa |
Lipid nanoparticle compositions and methods for formulating insoluble drugs
|
|
EP4499607A1
(en)
|
2022-03-25 |
2025-02-05 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
|
CA3250262A1
(en)
|
2022-04-27 |
2025-02-04 |
Shanghai Regenelead Therapies Co., Ltd |
NUCLEIC ACID CONSTRUCTION AND ITS USES
|
|
US20250295687A1
(en)
|
2022-05-09 |
2025-09-25 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
TW202409283A
(zh)
|
2022-05-13 |
2024-03-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
雙股ｄｎａ組合物及相關方法
|
|
TW202400784A
(zh)
|
2022-05-13 |
2024-01-01 |
大陸商上海瑞宏迪醫藥有限公司 |
包含utr的核酸構建體及其應用
|
|
WO2023218431A1
(en)
|
2022-05-13 |
2023-11-16 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2023230295A1
(en)
|
2022-05-25 |
2023-11-30 |
BioNTech SE |
Rna compositions for delivery of monkeypox antigens and related methods
|
|
CA3248209A1
(en)
|
2022-05-25 |
2023-11-30 |
CureVac SE |
Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
|
|
EP4531819A2
(en)
|
2022-05-25 |
2025-04-09 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
CN119562807A
(zh)
|
2022-05-30 |
2025-03-04 |
生物技术公司 |
用于递送核酸的复合物
|
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
WO2023250112A1
(en)
|
2022-06-22 |
2023-12-28 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
CN114989182B
(zh)
*
|
2022-06-23 |
2023-06-23 |
尧唐(上海)生物科技有限公司 |
脂质化合物、包含其的组合物及应用
|
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2024022263A1
(zh)
*
|
2022-07-25 |
2024-02-01 |
苏州艾博生物科技有限公司 |
脂质化合物和脂质纳米颗粒组合物
|
|
AU2023317702A1
(en)
|
2022-08-01 |
2025-01-09 |
BioNTech SE |
Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
|
|
AU2023320333A1
(en)
|
2022-08-01 |
2025-01-16 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
|
US20260048110A1
(en)
|
2022-08-03 |
2026-02-19 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
WO2024027910A1
(en)
|
2022-08-03 |
2024-02-08 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
WO2024044147A1
(en)
*
|
2022-08-23 |
2024-02-29 |
Modernatx, Inc. |
Methods for purification of ionizable lipids
|
|
AU2023329397A1
(en)
*
|
2022-08-26 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Pegylated lipid compounds and methods of use thereof
|
|
EP4581012A2
(en)
|
2022-08-31 |
2025-07-09 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
US20260076914A1
(en)
*
|
2022-09-11 |
2026-03-19 |
Barcode Nanotech Ltd. |
Ionizable lipids and compositions comprising same
|
|
AU2023343844A1
(en)
*
|
2022-09-19 |
2025-04-10 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Method for preparing 2-hydroxyethyl aminocaproate compound and use thereof
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
AU2023347390A1
(en)
|
2022-09-23 |
2025-04-10 |
BioNTech SE |
Compositions for delivery of plasmodium csp antigens and related methods
|
|
CN120225219A
(zh)
|
2022-09-23 |
2025-06-27 |
生物技术欧洲股份公司 |
用于递送肝期抗原的组合物及相关方法
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
AU2023357320A1
(en)
|
2022-10-06 |
2025-04-17 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
GB202215200D0
(en)
|
2022-10-14 |
2022-11-30 |
Mercurna B V |
Novel ionizable lipids
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
EP4608442A1
(en)
|
2022-10-28 |
2025-09-03 |
GlaxoSmithKline Biologicals S.A. |
Nucleic acid based vaccine
|
|
EP4612296A1
(en)
|
2022-10-31 |
2025-09-10 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
TW202434728A
(zh)
|
2022-11-08 |
2024-09-01 |
美商旗艦先鋒創新有限責任公司 |
用於產生環狀多核糖核苷酸的組成物和方法
|
|
EP4634376A2
(en)
|
2022-12-13 |
2025-10-22 |
Bayer Aktiengesellschaft |
Engineered type v rna programmable endonucleases and their uses
|
|
WO2024129988A1
(en)
|
2022-12-14 |
2024-06-20 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for delivery of therapeutic agents to bone
|
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|
|
EP4637718A1
(en)
*
|
2022-12-21 |
2025-10-29 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid nanoparticles comprising sterol-modified phospholipids
|
|
EP4642797A1
(en)
|
2022-12-28 |
2025-11-05 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2024151685A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
TW202438673A
(zh)
|
2023-01-09 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
疫苗及相關方法
|
|
WO2024153324A1
(en)
|
2023-01-18 |
2024-07-25 |
BioNTech SE |
Rna formulations for pharmaceutical use
|
|
JP2026503550A
(ja)
*
|
2023-01-20 |
2026-01-29 |
ポセイダ セラピューティクス，インコーポレイティド |
リピドイド化合物ならびに関連する組成物および使用
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
WO2024165146A1
(en)
|
2023-02-07 |
2024-08-15 |
Biontech Cell & Gene Therapies Gmbh |
Immune effector cells stably and transiently expressing nucleic acids
|
|
EP4665736A2
(en)
|
2023-02-13 |
2025-12-24 |
Flagship Pioneering Innovations VII, LLC |
Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
|
|
AU2024222598A1
(en)
|
2023-02-17 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified uracil
|
|
JP2026507514A
(ja)
|
2023-02-17 |
2026-03-04 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
修飾されたシトシンを含むｄｎａ組成物
|
|
WO2024175604A1
(en)
|
2023-02-21 |
2024-08-29 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of sanfilippo syndrome type iiib
|
|
CN121002196A
(zh)
|
2023-02-28 |
2025-11-21 |
百欧恩泰欧洲股份公司 |
用于多种编码核酸的接头序列效力测定
|
|
WO2024180363A1
(en)
|
2023-02-28 |
2024-09-06 |
BioNTech SE |
Linker sequence potency assays for multiple coding nucleic acids
|
|
JP2026509258A
(ja)
|
2023-03-08 |
2026-03-17 |
キュアバック エスイー |
核酸送達のための新規な脂質ナノ粒子製剤
|
|
CN121127584A
(zh)
|
2023-03-09 |
2025-12-12 |
生物技术公司 |
具有杀细菌活性的肽聚糖水解酶
|
|
AU2024235803A1
(en)
|
2023-03-15 |
2025-09-25 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising polyribonucleotides and uses thereof
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
CN118666726A
(zh)
*
|
2023-03-17 |
2024-09-20 |
尧唐(上海)生物科技有限公司 |
递送治疗剂的脂质化合物及其制备方法与应用
|
|
WO2024194767A1
(en)
|
2023-03-17 |
2024-09-26 |
BioNTech SE |
Automated drug production system
|
|
WO2024193827A1
(en)
|
2023-03-23 |
2024-09-26 |
BioNTech SE |
Stabilized nucleic acid compositions and methods for preparing, storing and using the same
|
|
WO2024209418A1
(en)
|
2023-04-07 |
2024-10-10 |
BioNTech SE |
Heating and cooling jacket for fluid vessels
|
|
JP2026514004A
(ja)
|
2023-04-12 |
2026-05-01 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
修飾されたｔｒｅｍ、組成物及びその関連方法
|
|
EP4695391A1
(en)
|
2023-04-12 |
2026-02-18 |
Flagship Pioneering Innovations VI, LLC |
Trems for use in correction of missense mutations
|
|
WO2024213776A1
(en)
|
2023-04-14 |
2024-10-17 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
CN121398842A
(zh)
|
2023-04-14 |
2026-01-23 |
百欧恩泰欧洲股份公司 |
用于预防或治疗结核病的rna
|
|
WO2024216217A1
(en)
|
2023-04-14 |
2024-10-17 |
BioNTech SE |
Hiv vaccine
|
|
EP4694919A1
(en)
|
2023-04-14 |
2026-02-18 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
EP4721759A1
(en)
*
|
2023-04-29 |
2026-04-08 |
Cansino (Shanghai) Biological Research Co., Ltd. |
Lipid nanoparticle for delivering nucleic acid drug, and preparation method therefor and use thereof
|
|
AU2024266138A1
(en)
|
2023-05-03 |
2025-11-13 |
Manifold Biotechnologies, Inc. |
Methods and compositions for high-throughput protein delivery, screening, and detection
|
|
AU2024265158A1
(en)
|
2023-05-03 |
2025-11-06 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
DE102023001946A1
(de)
|
2023-05-12 |
2024-11-14 |
Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts |
Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
|
|
IL324634A
(en)
|
2023-05-15 |
2026-01-01 |
Nchroma Bio Inc |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024236336A1
(en)
|
2023-05-17 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Lipc variant in the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
EP4722368A1
(en)
|
2023-05-26 |
2026-04-08 |
Samsung Biologics Co., Ltd. |
Novel nucleic acid construct comprising poly(a) tail having secondary or tertiary structure and uses thereof
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
AU2024310564A1
(en)
|
2023-06-29 |
2025-11-27 |
BioNTech SE |
Modular multiplatform system for mrna drug production
|
|
CN121532514A
(zh)
|
2023-07-07 |
2026-02-13 |
上海环码生物医药有限公司 |
用于季节性流感的环状rna疫苗及使用方法
|
|
IL325865A
(en)
|
2023-07-21 |
2026-03-01 |
BioNTech SE |
Compositions for administering Plasmodium antigens and related methods
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025021277A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Agents and methods for targeted delivery of cytokines to immune cells
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
US20250092426A1
(en)
|
2023-07-25 |
2025-03-20 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
KR20250018367A
(ko)
|
2023-07-28 |
2025-02-05 |
한국과학기술원 |
히스톤 코드 리더 도메인을 포함하는 폴리펩티드 및 이의 용도
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025027089A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thiolipids and uses thereof
|
|
WO2025026553A1
(en)
|
2023-08-02 |
2025-02-06 |
BioNTech SE |
Agents and methods for targeted delivery to cells
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
CN121772938A
(zh)
|
2023-08-03 |
2026-03-31 |
百欧恩泰欧洲股份公司 |
用于递送单纯疱疹病毒抗原的药物组合物及相关方法
|
|
NL2035538B1
(en)
|
2023-08-03 |
2025-02-18 |
Univ Eindhoven Tech |
Lipid-like copolymers and method of producing these and the use thereof, pharmaceutical compositions comprising said copolymers, and the use of said compositions.
|
|
CN121866336A
(zh)
|
2023-08-03 |
2026-04-14 |
百欧恩泰欧洲股份公司 |
靶向hiv的rna组合物
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025032158A1
(en)
|
2023-08-08 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat tauopathies
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
CN119591513A
(zh)
*
|
2023-09-11 |
2025-03-11 |
苏州星核迪赛生物技术有限公司 |
局部递送药物的材料及其应用
|
|
AU2024343011A1
(en)
|
2023-09-11 |
2026-03-26 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
TW202525266A
(zh)
|
2023-09-18 |
2025-07-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
可電離類脂質組成物及其治療用途
|
|
WO2025061863A1
(en)
|
2023-09-20 |
2025-03-27 |
BioNTech SE |
Method
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025073890A1
(en)
|
2023-10-06 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Method to capture circulating tumor extracellular vesicles
|
|
CN121969744A
(zh)
|
2023-10-06 |
2026-05-01 |
拜耳公司 |
工程化v型rna可编程核酸内切酶及其用途
|
|
TW202527962A
(zh)
|
2023-10-31 |
2025-07-16 |
德商拜恩技術股份公司 |
粒子、組合物及方法
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025106670A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
TW202539697A
(zh)
|
2023-11-15 |
2025-10-16 |
德商拜恩技術股份公司 |
冠狀病毒疫苗
|
|
WO2025106738A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|
|
TW202523695A
(zh)
|
2023-11-22 |
2025-06-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於治療非酒精性脂肪性肝病之方法及組成物
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
TW202532053A
(zh)
*
|
2023-12-13 |
2025-08-16 |
大陸商上海瑞宏迪醫藥有限公司 |
用於遞送治療劑的組成物和化合物
|
|
WO2025126071A1
(en)
|
2023-12-14 |
2025-06-19 |
Pfizer Inc. |
Rna molecules
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
TW202525287A
(zh)
|
2023-12-21 |
2025-07-01 |
德商拜恩技術運輸科技有限責任公司 |
可離子化脂質
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025157848A1
(en)
|
2024-01-23 |
2025-07-31 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the intravenous treatment of sanfilippo syndrome type iiib
|
|
TW202545974A
(zh)
|
2024-01-26 |
2025-12-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫受體抑制蛋白及相關方法
|
|
WO2025166325A1
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
MODIFIED GUIDE RNAs
|
|
WO2025186293A1
(en)
|
2024-03-06 |
2025-09-12 |
Institut National de la Santé et de la Recherche Médicale |
Chmp2b mutants for use for treating infection
|
|
WO2025186725A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Improved lnp formulations and uses thereof
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025202213A1
(en)
|
2024-03-26 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
CN118319880B
(zh)
*
|
2024-04-15 |
2025-02-07 |
荣灿生物医药技术(上海)有限公司 |
靶向肺部高效递送核酸的脂质纳米颗粒、吸入式制剂及应用
|
|
WO2025224684A1
(en)
|
2024-04-24 |
2025-10-30 |
BioNTech SE |
Compositions and methods for producing engineered immune cells
|
|
WO2025228975A1
(en)
|
2024-04-29 |
2025-11-06 |
BioNTech SE |
Particles, compositions and methods
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025264662A1
(en)
|
2024-06-18 |
2025-12-26 |
BioNTech SE |
Compositions and methods for treatment of melanoma
|
|
WO2025262460A1
(en)
|
2024-06-21 |
2025-12-26 |
BioNTech SE |
Lipid compositions for nucleic acid delivery
|
|
WO2026006196A1
(en)
|
2024-06-24 |
2026-01-02 |
Avanti Polar Lipids, Llc |
Conical shaped diacyl glyceroethylphosphocholines as cationic lipids and uses thereof
|
|
WO2026005944A1
(en)
|
2024-06-24 |
2026-01-02 |
Avanti Polar Lipids, Llc |
Piperazine based divalent ionizable lipids and their uses
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026015882A1
(en)
|
2024-07-12 |
2026-01-15 |
BioNTech SE |
Hsv antigen fragments and related methods
|
|
WO2026018181A1
(en)
|
2024-07-17 |
2026-01-22 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
WO2026018213A1
(en)
|
2024-07-18 |
2026-01-22 |
Vaxthera Sas |
A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
|
|
WO2026021698A1
(en)
|
2024-07-23 |
2026-01-29 |
BioNTech SE |
Nucleic acid particle
|
|
WO2026037391A1
(en)
*
|
2024-08-16 |
2026-02-19 |
Shanghai Vitalgen Biopharma Co., Ltd. |
Compositions and methods for Antigen-presenting cell-specific delivery of nucleic acids
|
|
WO2026041793A1
(en)
|
2024-08-23 |
2026-02-26 |
BioNTech SE |
Chimeric proteins comprising non-human protein domains for enhancing antigenicity
|
|
WO2026047153A1
(en)
|
2024-08-28 |
2026-03-05 |
BioNTech SE |
Potency assay for multiple coding nucleic acids
|
|
WO2026047603A1
(en)
|
2024-08-28 |
2026-03-05 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|
|
WO2026047148A1
(en)
|
2024-08-29 |
2026-03-05 |
BioNTech SE |
Minimal polypeptide-encoding rnas
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026057625A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having a chap domain with engineered active site
|
|
WO2026057626A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having multiple enzymatically active domains
|
|
WO2026064313A1
(en)
|
2024-09-17 |
2026-03-26 |
Flagship Pioneering Innovations Vii, Llc |
Rna compositions and related methods
|
|
WO2026073260A1
(en)
*
|
2024-09-30 |
2026-04-02 |
Flagship Pioneering Innovations Vi, Llc |
Lipid nanoparticle formulations of trems
|
|
WO2026068864A1
(en)
|
2024-09-30 |
2026-04-02 |
BioNTech SE |
Engineered ch1 and cl domains for the prevention of chain mispairing
|
|
WO2026085300A1
(en)
|
2024-10-16 |
2026-04-23 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
WO2026082899A2
(en)
|
2024-10-16 |
2026-04-23 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
WO2026088119A1
(en)
|
2024-10-24 |
2026-04-30 |
Pfizer Inc. |
Lipidated tlr7/8 modulators as adjuvants and uses thereof
|
|
WO2026093414A1
(en)
|
2024-10-30 |
2026-05-07 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising membrane il-35
|